Skip to main content
PrintBio is a privately held, clinical- and commercial-stage biotechnology company and leader in regenerative medicine using novel 3D-bioprinting and material science technologies to deliver safe, functional and personalized products and living tissues and organs, engineered and produced on-demand for patients.  The Company was founded and is led by an experienced team of biotechnology founders and executives.

 

For questions regarding investment opportunities, email: investors@printbio.com

Learn More

PrintBio Contributes 3D Bioprinting Expertise to ARPA-H PRINT Program for Kidney Bioprinting

| Press Releases | No Comments
PrintBio, a regenerative medicine and bioprinting company, today announced its participation in a major ARPA-H PRINT Program initiative aimed at addressing the nation’s growing organ shortage through the development of…

Ponce Aurora Appoints Former Estee Lauder Executive as Chief Commercial Officer Ahead of Longevity Product Launches

| Press Releases | No Comments
Ponce Aurora is developing consumer products powered by its proprietary MitoXcel™ Technology, the first information- and AI-driven mitochondrial-targeted geropeptides addressing a fundamental cause of aging.  Appointment strengthens leadership team to drive market readiness for YUUTH- and…

PrintBio Introduces DynaFlex™ Programmable Surgical Mesh (PSM) at American Hernia Society Meeting 2025

| Press Releases | No Comments
DynaFlex™ Incorporates MetaDirectional Flex™ Technology to Create the First-of-Its-Kind Programmable Mesh Our introduction of DynaFlex™ represents a new era in surgical repair. By giving surgeons programmable control over mesh mechanics,…